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mL in MitraClip and surgery groups respectively; LV end-systolic volumes decreased by
6 mL and 11 mL respectively. 97% of MitraClip and 98% of surgery patients were
NYHA-FC I/II.
Conclusions: Both the MitraClip device and MV surgery confer clinical benefits through
3 years similar to EVEREST II results at 1 year and 2 years, with sustained reduction in
MR and sustained improvement in LV volumes and NYHA-FC. Although there is a 22%
rate of surgery within 6 months post-index MitraClip procedure, this rate remains stable
thereafter. Despite larger reductions in LV volumes and MR severity in the surgery group,
both groups experienced similar levels of sustained improvement in NYHA-FC at 3 years.
The MitraClip device may be considered a transcatheter therapeutic option for select
patients with severe MR.
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Background: Transcatheter paravalvular leak closure (TPVLC) has become a well-
established alternative to reoperation. Implantation of multiple smaller plugs is postulated
to outperform a single large one. Still, the procedural success pivots on optimal choice of
occluding devices, which has not been standardized as yet.
Methods: We enrolled 16 patients with mitral (n10) or aortic paravalvular leak (PVL)
scheduled for TPVLC. In each case PVL channel area (PVLCA) was estimated according
to its minimum and maximum diameters in the plane parallel to prosthesis’ sewing ring
with use of transesophageal echocardiography (TEE). We also calculated the middle
module area (MMA) for different sizes of AVPs III according to their length and width
as provided by manufacturer. Then, in a 1-stage procedure, 2 AVPs III of similar size were
implanted into each PVL either simultaneously or sequentially. Their added MMAs were
aimed to exceed the targeted PVLCA by 10-30%.
Results: The mean ratio of maximum to minimum PVL diameter was 2.32. The mean
estimated PVLCA [mm2] was 60.7 with median of 44.5, minimum 24 and maximum of
148. The mean value of occluders’ added MMAs exceeded corresponding PVLCA by
27.7%. Optimal effect defined by total occlusion or trivial residual PVL by TEE was
achieved in 13 patients. When technical challenges disabled the intended oversizing
(n3) a moderate residual PVL was present - see Figure 1.
Conclusions: Implantation of 2 AVPs III with approximately 30% area oversizing
ensures complete TPVLC in patients with oblong PVL.
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Background: Mitral regurgitation (MR) of functional vs. degenerative origin are
different morphological entities that have mostly been grouped together in studies
published to date on MitraClip therapy. We sought to identify factors predicting the
long-term clinical outcome following MitraClip implantation according to the underlying
etiology.
Methods: By April 2012, 270 consecutive patients (74  9 years, 172 men) with
significant MR not amenable to surgery underwent MitraClip therapy at our center.
Functional (FMR) and degenerative/mixed MR (DMR) were present in 184 (68%) and 86
patients, respectively. We performed survival analyses (Kaplan-Meier, Cox regression) of
230 patients followed.
Results: Cumulative survival at 2 years did not differ between DMR and FMR patients
(65.3 [95% CI, 55.7-74.9]% vs. 60.5 [45.7-75.4]%, p0.855); however, at 2 years,
rehospitalizations occurred significantly more often in FMR patients (70.5 [59.3-81.7]%
vs. 49.6 [37.3-62.0]%, p0.023 by 12-month-landmark analysis) and mitral valve surgery
was needed significantly more often in DMR patients (20.0 [9.2-30.9]% vs. 5.0
[0.7-9.2]%, p0.002). Uni- and multivariate Cox regression revealed that for both FMR
and DMR left ventricular dilatation was independently predictive of rehospitalization.
Independent predictors of reintervention were an anterior mitral leaflet length30 mm for
DMR, and an eccentric MR jet and increasing left atrial area for FMR.
Conclusions: As shown for this high-risk patient population, MR etiology did not impact
on survival following MitraClip, however, clear differences between FMR and DMR were
observed with respect to rehospitalization and reintervention: Whereras treatment of DMR
is linked to increased reinterventions, the increased rate of rehospitalization in patients
treated for FMR reflects the increased degree of LV dysfunction.
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Background: Corrective surgery for functional mitral regurgitation (FMR) has proven
beneficial in that it improves NYHA functional class and induces reverse left ventricular
remodeling. However, proof of survival benefit is pending. Percutaneous techniques of
mitral valve repair (MVR) may become a viable treatment alternative for high-risk
patients with severe FMR.
Methods: We retrospectively analyzed our prospective hospital database of patients with
severe FMR undergoing percutaneous treatment using the MitraClip device or surgical
MVR. Patient characteristics and acute and 6-month hemodynamic and clinical outcomes
are reported.
Results: 95 patients were treated using the MitraClip device while 76 patients underwent
isolated surgical MVR for FMR. Patients undergoing MitraClip treatment were signifi-
cantly older (mean72.48.1vs.64.511.4 years,p0.001), had a lower left ventricular
ejection fraction (mean36.212.5%vs.42.116.2%,p0.014), and were generally more
high-risk, with a significantly higher mean logEuroSCORE compared to surgical
candidates (33.718.7vs.10.18.7%,p0.001). Procedural success was 95.8% (91/95)
for MitraClip treatment and 93.4% (71/76) for surgery (p0.491). 30-day mortality was
4.2% (4/95) and 2.6% (2/76;p0.557) and mean grade of residual MR was 1.40.8 and
0.20.4 (p0.001) after MitraClip treatment and surgical MVR respectively. Unadjusted
survival rates after 6 months were 87% and 96% for MitraClip and surgical treatment
respectively. However, after multivariate regression analysis and adjustment for baseline
differences, survival differences were no longer statistically significant (p0.358).
Conclusions: Patients with FMR undergoing surgery differ significantly from those
considered for percutaneous therapy. Surgery was more effective compared to MitraClip
in reducing MR. However, a large proportion of patients benefits from percutaneous
intervention with sustained MR2	 at 6 months. Especially for elderly patients with
reduced left ventricular function and relevant comorbidities, MitraClip therapy seems to
be an adequate alternative to surgery. Assessment, treatment and postprocedural care of
patients by an interdisciplinary team is of paramount importance for clinical success.
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Background: Due to the implantation of one or more MitraClips in patients with mitral
valve regurgitation, a decrease in mitral valve area (MVA) is created, which has not been
shown to result in clinical significant mitral stenosis. However mitral inflow patterns were
only measured in these patients during resting conditions. Therefore we aimed to
investigate the effect of MitraClip implantation on mitral valve pressure gradient (MVPG)
during exercise.
Methods: We included 23 patients with symptomatic severe mitral regurgitation (age
768 years, 44% male) who underwent MitraClip implantation with placement of one or
more clips. Transthoracic echocardiography was performed pre-procedural and at follow
up after MitraClip implantation (median follow up: 13 months) to measure the mean and
maximum MVPG with continuous wave Doppler in rest and during bicycle exercise test.
Results: NYHA functional class was significantly decreased after MitraClip from class
III to II (p0.001). Following MitraClip implantation the mean MVPG increased from
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